Condition: Solid Tumors · Sponsor: RemeGen Co., Ltd.
The primary objective is to evaluate the safety and tolerability of RC278; determine the maximum tolerated dose (MTD) and/or maximum administered dose (MAD) of RC278; and determine the recommended phase 2 dose (RP2D)， and assess the efficacy of RC278 at the RP2D dose;
This description comes directly from the study's public registry record.
Xiaohong Su · +8610-65018841 · na.su@remegen.com
Always discuss trial participation with your own doctor first.
| Cancer Hospital Chinese Academy of Medical Sciences | Beijing, Beijing Municipality, China | Recruiting |
| Fujian Cancer Hospital | Fuzhou, Fujian, China | Recruiting |
| Fujian Cancer Hospital | Fuzhou, Fujian, China | Recruiting |
| Fujian Medical University Union Hospital | Fuzhou, Fujian, China | Recruiting |
| The First Affiliated Hospital of Xiamen University | Xiamen, Fujian, China | Recruiting |
| The Second Affiliated Hospital of Guilin Medical University | Guilin, Guangxi, China | Recruiting |
| Guangxi Medical University Cancer Hospital & Guangxi Cancer Institute | Nanning, Guangxi, China | Recruiting |
| Harbin Medical University Cancer Hospital | Harbin, Heilongjiang, China | Recruiting |
| Anyang Cancer Hospital | Luoyan, Henan, China | Recruiting |
| The First Affiliated Hospital of Henan University of Science &Technology | Luoyang, Henan, China | Recruiting |
| Nanyang Second General Hospital | Nanyang, Henan, China | Recruiting |
| The First Affiliated Hospital of Xinxiang Medical University | Xinxiang, Henan, China | Recruiting |
+ 27 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07105215